<DOC>
	<DOCNO>NCT02203760</DOCNO>
	<brief_summary>Study design : This study prospective , randomize , open-label , multicenter phase II trial order determine progression-free survival patient refractory relapse metastatic uterine leiomyosarcoma metastatic uterine tumour . Indication : Relapsed metastatic uterine leiomyosarcoma carcinosarcoma Randomization : Patients uterine leiomyosarcomas randomize 1:1-fashion receive follow therapy - Arm A : Pazopanib 800 mg orally daily plus Gemcitabine 1000 mg/m2 i.v . 30 min 1 8 q3w - Arm B : Pazopanib 800 mg orally daily Patients uterine carcinosarcoma treat accord Arm A . Planned number patient : 87 patient uterine leiomyosarcomas 20 patient uterine carcinosarcomas Treatment schedule : Patients uterine leiomyosarcomas randomize 1:1-fashion receive follow therapy • Arm A ( experimental arm / combination arm ) : Pazopanib 800 mg orally daily plus Gemcitabine 1000 mg/m2 i.v . 30 min 1 8 q3w • Arm B ( control arm / monotherapy arm ) : Pazopanib 800 mg orally daily Patients uterine carcinosarcoma treat accord Arm A . Planned treatment duration per subject : Patients continue study treatment disease progression , death , unacceptable toxicity withdrawal consent reason .</brief_summary>
	<brief_title>Pazopanib vs. Pazopanib Plus Gemcitabine Patients With Relapsed Metastatic Uterine Leiomyosarcomas Uterine Carcinosarcomas : Multi-center , Randomized Phase-II Clinical Trial NOGGO AGO - PazoDoble -</brief_title>
	<detailed_description />
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Carcinosarcoma</mesh_term>
	<mesh_term>Mixed Tumor , Mullerian</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Subjects must provide informed consent prior performance studyspecific procedures assessment , must willing comply treatment followup . Procedures conduct part subject 's routine clinical management ( e.g. , blood count , image study ) obtain prior signing inform consent may utilize screen baseline purpose provide procedure conduct specify protocol 2 . Histologically cytological confirm uterine leiomyosarcoma uterine carcinosarcoma include subtypes 3 . Patient must receive one two prior chemotherapy 4 . For patient prior anthracycline therapy normal cardiac function LVEF least 50 % must assess quantitative echocardiogram MUGA scan 5 . Prior Gemcitabine contain chemotherapy permit provide least 8 week elapse since last dose therapy 6 . ECOG performance status 01 7 . At least 18 year old 8 . Measurable disease accord RECIST v 1.1 criterion ( case tumour debulking stag CTscan surgery ) 9 . Able swallow retain oral medication 10 . Adequate organ system function define Table 1 Table 1 : Definitions Adequate Organ Function System Laboratory Values Hematologic Absolute neutrophil count ( ANC ) &gt; = 1.5 X 109/L Hemoglobin1 &gt; = 9 g/dL ( 5.6 mmol/L ) Platelets &gt; = 100 X 109/L Prothrombin time ( PT ) international normalize ratio ( INR ) 4 &lt; = 1.2 X upper limit normal ( ULN ) Partial thromboplastin time ( PTT ) &lt; =1.2 X ULN Hepatic2 Total bilirubin &lt; = 1.5 X ULN AST ALT &lt; = 2.5 X ULN Renal Serum creatinine &lt; = 1.5 mg/dL ( 133 µmol/L ) Or , great 1.5 mg/dL : Calculated creatinine clearance &gt; = 50 mL/min Urine Protein Creatinine Ratio ( UPC ) 3 &lt; 1 1 . Subjects may transfusion within 7 day prior screen assessment . 2 . Concomitant elevation bilirubin AST/ALT 1.0 x ULN permit 3 . If UPC &gt; = 1 , 24hour urine protein must assess . Subjects must 24hour urine protein value &lt; 1g eligible . 4 . Subjects receive anticoagulant therapy eligible INR stable within recommended range desire level anticoagulation 11 . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include female : A hysterectomy A bilateral oophorectomy ( ovariectomy ) A bilateral tubal ligation Is postmenopausal Subjects use hormone replacement therapy ( HRT ) must experience total cessation menses ≥ 1 year great 45 year age , OR , questionable case , follicle stimulate hormone ( FSH ) value &gt; 40 mIU/mL estradiol value &lt; 40pg/mL ( &lt; 140 pmol/L ) . Subjects use HRT must experience total cessation menses &gt; = 1 year great 45 year age OR document evidence menopause base FSH estradiol concentration prior initiation HRT OR Negative serum pregnancy test woman childbearing potential perform within 1 week prior first dose study treatment , preferably close first dose possible , agree use adequate contraception . Acceptable contraceptive method , use consistently accordance product label instruction physicians follow 14 day exposure investigational product , dose period least 21 day last dose investigational product : Complete abstinence sexual intercourse Oral contraceptive , either combined progestogen alone Injectable progestogen Implants levonorgestrel Estrogenic vaginal ring Percutaneous contraceptive patch Intrauterine device ( IUD ) intrauterine system ( IUS ) document failure rate le 1 % per year Male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study , male sole partner subject Double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) vaginal spermicidal agent ( foam/gel/film/cream/suppository ) Female subject lactate discontinue nursing prior first dose study drug refrain nursing throughout treatment period 14 day follow last dose study drug . 1 . Prior malignancy • Note : Subjects another malignancy diseasefree 5 year , subject history completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma eligible . 2 . Patient receive prior treatment antiangiogenic agent include bevacizumab tyrosine kinase inhibitor 3 . Active malignancy malignancy last 5 year prior first dose study drug LMS CS 4 . History clinical evidence central nervous system ( CNS ) leptomeningeal metastasis , except individual previouslytreated CNS metastasis , asymptomatic , requirement steroid antiseizure medication 6 month prior first dose study drug . Screening CNS image study ( compute tomography [ CT ] magnetic resonance image [ MRI ] ) require clinically indicated subject history CNS metastases 5 . Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding include , limited : Active peptic ulcer disease Known intraluminal metastatic lesion/s risk bleed Inflammatory bowel disease ( e.g . ulcerative colitis , Crohn 's disease ) , gastrointestinal condition increase risk perforation History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 28 day prior begin study treatment Grade 3/4 diarrhea 6 . Corrected QT interval ( QTc ) &gt; 450 Milliseconds use Barzett 's formula 7 . History one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting Myocardial infarction Unstable angina Coronary artery bypass graft surgery Symptomatic peripheral vascular disease Class III IV congestive heart failure , define New York Heart Association ( NYHA ) Poorly control hypertension [ define systolic blood pressure ( SBP ) ≥140 mmHg diastolic blood pressure ( DBP ) ≥ 90 mmHg ] . Note : Initiation adjustment antihypertensive medication ( ) permit prior study entry . BP must reassess two occasion separate minimum 1 hour ; occasion , mean ( 3 reading ) SBP / DBP value BP assessment must &lt; 140/90 mmHg order subject eligible study ( refer study protocol detail BP control reassessment prior study enrollment ) 8 . History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . • Note : Subjects recent DVT treat therapeutic anticoagulating agent least 6 week eligible 9 . Major surgery trauma within 28 day prior study enrolment non heal wound , fracture ulcer ( procedure catheter placement consider major ) 10 . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate Pazopanib Gemcitabine 11 . Evidence active bleeding bleed diathesis 12 . Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel 13 . Hemoptysis excess 2.5 mL ( one half teaspoon ) within 8 week prior first dose study drug 14 . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedures 15 . Unable unwilling discontinue use prohibit medication list study protocol least 14 day five halflives drug ( whichever longer ) prior first dose study drug duration study 16 . Treatment follow anticancer therapy Radiation therapy , surgery tumour embolization within 14 day prior first dose study drug Chemotherapy , immunotherapy , biologic therapy , investigational therapy hormonal therapy within 14 day five halflives drug ( whichever longer ) prior first dose study drug 17 . Any ongoing toxicity prior anticancer therapy &gt; Grade 1 and/or progress severity , except alopecia 18 . Pregnancy ( woman childbearing potential confirm negative serum pregnancy test ) lactation period Women childbearing potential : miss contraception ( PearlIndex &lt; 1 , e.g . hormonal contraception include combined oral contraceptive pill , transdermal patch , contraceptive vaginal ring , intrauterine device sterilization ) 14 day exposure investigational product , study treatment least 21 day last dose investigational product . 19 . Medical psychological condition would permit subject complete study sign inform consent 20 . Legal incapacity limit legal capacity 21 . Participation another clinical study experimental therapy within 30 day prior study enrolment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Relapsed metastatic uterine leiomyosarcoma carcinosarcoma</keyword>
</DOC>